| pioglitazone / Generic mfg. |
2009-011675-79: A PHASE II STUDY TO ASSESS EFFICACY AND SAFETY OF PIOGLITAZONE (ACTOS®) AS ADD-ON THERAPY TO IMATINIB MESYLATE (GLEEVEC®) IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML) PATIENTS IN MAJOR MOLECULAR RESPONSE (MMR). |
|
|
| Ongoing | 2 | 50 | Europe | PIOGLITAZONE HYDROCHLORIDE, ACTOS 15 mg, ACTOS 15 mg | CH-Versailles | chronic phase chronic myelogenous leukaemia (CP-CML) patients in major molecular response. | | | | |
2015-005208-26: CANDIDATE THERAPIES IN COMBINATION OR SEQUENTIALLY WITH TYROSINE KINASE INHIBITORS IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML) PATIENTS IN COMPLETE CYTOGENETIC RESPONSE WITHOUT ACHIEVING A DEEP MOLECULAR RESPONSE: AN ADAPTIVE TRIAL BASED ON A DROP LOSER DESIGN. |
|
|
| Not yet recruiting | 2 | 100 | Europe | Tablet, ACTOS | Centre Hospitalier de Versailles, DGOS | CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML), CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML), Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
EDI-PIO, NCT02852486: Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response |
|
|
| Active, not recruiting | 2 | 31 | RoW | Pioglitazone 30 Mg Oral Tablet, cloridrato de pioglitazona 30mg EMS S/A, Brasil, imatinib discontinuation | University of Campinas, Brazil | Leukemia, Chronic Myeloid | 02/24 | 02/24 | | |
ACTIW, NCT02767063: Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR |
|
|
| Recruiting | 1/2 | 100 | Europe | Pioglitazone, Avelumab | Versailles Hospital | Leukemia, Myeloid, Chronic-Phase | 11/22 | 06/23 | | |
NCT03720366: A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients |
|
|
| Completed | 1 | 40 | RoW | enasidenib, CC-90007, AG-221, Arm 1 probes, Arm 2 Probes, Arm 3 probes | Celgene | Leukemia, Myeloid, Acute | 09/23 | 12/23 | | |
